Key Summary Points
Why carry out this study?Ankylosing spondylitis (AS) is associated with poor health-related quality of life, work productivity loss, and reduced ability to perform daily activities.Given that many patients with AS do not achieve disease control following treatment and the more recent introduction of oral advanced therapy (AT) options, it is important to consider patients’ preferences regarding treatment administration.This mixed-methods study tested preferences for AT treatment administration attributes among patients with AS based on AT experience and disease status.What was learned from this study?Overall, patients generally prefer oral over self-injection options, less frequent administration, and avoiding the need for doctor visits to receive treatment.Patients’ treatment preferences depend on whether they currently use AT and whether their disease is well controlled or not.Patients with AS who are AT naïve and do not have well-controlled disease have a strong preference for oral treatments, suggesting that injections may be a barrier to initiating AT, whereas for patients with AT experience, avoiding injections is less of a priority than reducing injection frequency.
Introduction
Ankylosing spondylitis (AS, also called radiographic axial spondyloarthritis or r-axSpA) is a chronic, immune-mediated inflammatory arthritis that primarily affects the sacroiliac joints and the spine, with disease activity increasing with age [1]. Symptoms of AS include pain and stiffness in the back and hips. Over time, back movement becomes more limited as the vertebrae fuse together.
AS can cause severe, chronic pain for those living with the disease [2].
AS is associated with a high disease burden for patients, as onset often occurs during young adulthood and their prime working years. AS-related pain and uncontrolled disease have a negative impact on patients’ health-related quality of life, work productivity, and ability to perform daily activities [3]. The pain and functional impairment attributed to AS is also associated with higher direct medical costs, with these costs estimated to increase by 26–76% for each one-point increase in Health Assessment Questionnaire Disability Index, a measure of functional disability [4].
The aim of AS treatment is thus to control disease symptoms, thereby improving functioning and preventing progressive structural damage.
According to the American College of Rheumatology (ACR), Spondylitis Association of America (SAA) and Spondyloarthritis Research and Treatment Network (SPARTAN) treatment guidelines, physical therapy (PT) and nonsteroidal anti-inflammatory drugs (NSAIDs) are the recommended first-line treatments for AS [5]. If NSAIDs fail to relieve symptoms, tumor necrosis factor inhibitors (TNFi) are preferred, with interleukin-17 inhibitors (IL-17i) prescribed in the event of primary nonresponse to an initial TNFi. Janus kinase inhibitors (JAKi) are considered for patients who do not have a response with TNFi or IL-17i [5].
Similarly, European Alliance of Associations for Rheumatology (EULAR) guidelines for AS management recommend PT and NSAIDs as first-line therapy; TNFi, IL-17i, or JAKi can be prescribed if high disease activity persists following conventional treatments [6].
Many patients who are not well controlled on conventional therapies do not receive guideline-recommended advanced therapies [7]. For many patients, AS is not well controlled, even with advanced therapies [8], underscoring the importance of considering patients’ preferences regarding treatment administration. Furthermore, given the variety of modes of administration and dosing frequencies across different advanced therapies for AS, it will be important to understand patients’ views on treatment delivery.
In prior studies of treatment preferences in r-axSpA and other inflammatory diseases, mode of administration was an important factor for patients when making treatment decisions [9–12]. Thus, we examined whether preferences for administration attributes vary between patients based on advanced therapy experience and disease control. Furthermore, because disease activity is associated with increases in age [1], we assessed whether preferences for administration attributes differ between younger and older patients.
To test for these potential differences, we conducted a mixed-methods study to understand the perceptions and preferences of patients with AS from multiple countries regarding attributes reflecting the process of treatment administration. The results of this study may inform shared decision-making by assisting physicians in understanding which patients may be better served by receiving treatment delivered by different modes of administration.
Methods
Study Design
This study involved qualitative interviews to identify treatment delivery attributes that are important to patients with AS, followed by an online survey to quantify preferences for these attributes. The study protocol, qualitative interview discussion guide, informed consent statement, and quantitative survey were reviewed by Sterling IRB (Atlanta, GA, USA), and an exemption determination was granted on July 26, 2022 (IRB ID #: 10267-MMaculaitis). To participate in either the qualitative interviews or the quantitative survey, patients provided their informed consent verbally or electronically, respectively.
The study was performed in accordance with the Helsinki Declaration of 1964 and its later amendments.
Qualitative Interviews
Eligible patients for the qualitative interviews were aged ≥ 18 years, resided in United States (US), had a confirmed AS diagnosis (i.e., patients provided screenshots of their medical records, patient portal, or AS medication), and had a score of ≥ 4 on the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) indicating that AS is not well controlled and that a change in drug therapy may be necessary to reduce disease activity [13]. Those who were currently enrolled in a clinical trial, had a diagnosis of Alzheimer’s disease or dementia, or who were unable to speak English (i.e., interviews were conducted in English) were ineligible to participate. A total of ten patients with AS were recruited to participate in the qualitative interviews.
Researchers have noted that data saturation may be attained by as little as 6–12 interviews, depending on the nature of the data being collected [14].
An experienced moderator conducted one-on-one interviews lasting approximately 45 min. A semi-structured interview guide was followed with open-ended questions to identify key attributes that influence treatment preference. Topics explored in the interview included patient experience and patient journey with AS and patient perceptions of AS treatment modes of administration.
Qualitative interview data were collected between February 16 and April 1, 2022.
Quantitative Survey
Patients with AS in the US, United Kingdom (UK), and one European country (Italy) were recruited to complete a cross-sectional, web-based, patient preference survey. Eligible patients were aged ≥ 18 years, resided in US, UK, or Italy, had confirmed AS diagnosis using the same verification options to confirm diagnosis used in the qualitative interviews described above, and met one or both of the following criteria: score of ≥ 4 on the BASDAI (i.e., not well-controlled disease) and/or currently taking advanced therapy. These criteria were applied to categorize participants into three groups: on advanced therapy/well-controlled disease, on advanced therapy/not well-controlled disease, and not on advanced therapy/not well-controlled disease.
Data were collected between June 8, 2023 and October 5, 2023.
The survey included two preference elicitation assessments: a case 1 best–worst scaling (BWS) exercise [15], as well as six fixed-choice tasks. An object-case (case 1) BWS exercise was used to assess patient preferences for attributes representing the process of AS treatment administration (including attributes of biologic or targeted synthetic disease-modifying anti-rheumatic drugs [bDMARDs or tsDMARDs] administered via oral, subcutaneous [SC], or intravenous [IV] modes of administration). In a case 1 BWS, respondents are asked to rank the most desirable and least desirable items within a subset of a list of items in a series of questions in order to put the relative desirability of each item on a numerical scale [16, 17].
BWS yields a rank ordering of the importance of all items as well as a quantitative measure of the relative importance (RI) of each item. A total of 12 attributes related to the process of treatment administration were included as items in the BWS exercise. The attributes covered four general categories of processes reflecting treatment administration: mode of administration (e.g., oral/pill), frequency of administration (e.g., once a day), treatment accessibility/affordability (e.g., can be delivered to your home), and characteristics of the treatment (e.g., does not require refrigeration).
Attributes included in the BWS exercise are shown in Table 1; an example BWS question is shown in Fig. 1. Each BWS question asked: “Assuming you are choosing a treatment for ankylosing spondylitis (AS), which of the following things about a treatment would you like the most, and which would you like the least?” This study followed the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) guidelines on conducting conjoint analysis [18–20].Table 1BWS exercise attributesAttribute labelAttribute descriptionOral/pillTreatment taken orally (by mouth)Self-injectionTreatment taken by self-injection (under the skin)Frequency: QDTreatment taken once a dayFrequency: BIDTreatment taken twice a dayFrequency: 1 × monthTreatment taken once a monthFrequency: 2 × monthTreatment taken twice a monthRefrigerationTreatment does not need to be kept refrigeratedWasting doseThere is no chance of accidentally wasting a doseHome deliveryTreatment can be delivered to your homeAffordableSame cost or no cost of treatment to manage my ankylosing spondylitisSize of treatmentTreatment is easy to fit in your coat pocketDoes not require an office visitTreatment does not need to be taken at a doctor’s office or clinicAttribute labels were not shown to respondents in the BWS choice tasks.
BID twice a day, BWS best–worst scaling, QD once a dayFig. 1Example best–worst scaling item
The fixed-choice tasks were designed to directly elicit preferences regarding mode and frequency of AS treatment administration. Each fixed-choice task presented two options and asked the individual to report whether Option A is preferred, Option B is preferred, or they have no preference. In the fixed-choice tasks, the frequency of administration shown for ‘pill’ (once a day, twice a day) and ‘self-injection’ (once a month, twice a month) were varied to enable pairwise comparisons between the four frequency and mode of administration options; the instructions for each task told patients to assume that the options presented do not differ in effectiveness or side effects and that any self-injected medication requires refrigeration.
In addition to treatment preferences assessed via fixed-choice tasks and BWS exercise, the survey included other items to characterize the study sample on sociodemographic and clinical characteristics and AS treatment use.
Data Analysis
Qualitative Interviews
A content and thematic analysis of the interview data was performed. Thematic analysis is a method for identifying, analyzing, and reporting patterns (themes) within data [21]. The verbatim transcripts were uploaded to a qualitative data analysis program (NVivo v12), which enabled an assignment of codes to the emerging themes and facilitated organization of the data.
One researcher reviewed the first two transcripts and developed an initial coding system, specifying key themes and sub-themes. The draft code system and respective transcripts were reviewed by a second researcher. The code system was refined throughout the analysis, where applicable.
Saturation was tracked and confirmed through a saturation grid, which was used to compare and tally themes elicited during each interview. Information saturation, in which no new key themes emerge with each successive interview, was attained by the last interview.
Quantitative Survey
For patient characteristics, including current treatment use, means and standard deviations (SDs), medians, first and third quartiles (Q1 and Q3), minimums, and maximums were provided when performing descriptive analysis of continuous or discrete (i.e., count) data. Frequencies and percentages were provided when performing descriptive analysis of categorical data.
To estimate RI for each attribute in the BWS, hierarchical Bayesian (HB) estimation was fitted to the BWS data [22]. The HB model yields a coefficient for each item in the BWS for each respondent. These coefficients were assumed to be drawn from a multivariate normal distribution across respondents in the sample (the higher level of the model).
The coefficients for a respondent were used in a logit model for the task where one selects the best and worst from a group of items. The best item was chosen in a logistic regression model, so the components of the regression model are: exp(A)/(exp(A) + exp(B) + exp(C) + exp(D)). In the BWS, the worst item is also chosen in a logistic regression model, but the item that was chosen as best is dropped, negating the coefficients.
Hence, the components in the regression model for choosing B worst are: exp(-B)/(exp(-B) + exp(-C) + exp(-D)). The estimated coefficients were transformed with the logit and converted into RI scores and standardized to sum to 100 across attributes for reporting. The items were then rank-ordered by RI.
Further details on this analytic approach have been described previously [23].
Subgroup variables were derived from survey responses to BASDAI and current treatment. For the treatment/disease status subgroup, advanced treatment/well-controlled disease was defined as BASDAI < 4 and current use of any advanced therapy. Advanced treatment/not well-controlled disease was defined as BASDAI ≥ 4 and current use of any advanced therapy; no advanced treatment use/not well-controlled disease was defined as BASDAI ≥ 4 and no advanced therapy use.
The combination of no advanced treatment and well-controlled disease was not included because patients were required to have either poor disease control or be on advanced therapy to be eligible for the study. Sex and age subgroups were also created. Age 42 was used as the cut-off point (aged < 42 years, ≥ 42 years) based on the mean age of patients with AS who had received tofacitinib in a prior randomized clinical phase 3 trial [24].
RI estimates for each attribute across the three treatment/disease control subgroups and the two age subgroups were compared via one-way analysis of variance tests (ANOVAs) and two-sample t tests, respectively. P values < 0.05, two-tailed, were considered statistically significant. Frequencies and percentages were used to summarize fixed-choice task responses for the total sample and by subgroup.
BWS analyses were performed using Sawtooth’s Lighthouse Studio v9.13.1 (Provo, UT, USA). All other analyses were performed using IBM SPSS Statistics v28.0 (Armonk, NY, USA).
Results
Qualitative Interviews
Study Sample
Of the ten participants, the mean age was 46 years, and 60% were male and had at least a college degree. Half were currently working, and 30% were on disability or unable to work. Nearly all patients (≥ 90%) see a rheumatologist or primary care provider for their AS.
At the time of the study, the mean time since diagnosis was 11 (range 1–22) years; patients reported a mean of 8 (5–20) years from AS symptom onset to diagnosis.
Impacts of AS
Illustrative verbatim quotes from patients regarding the different impacts of AS are shown in Table 2. Patients most commonly cited pain (70.0%) and symptom unpredictability (50.0%) as the most bothersome disease-specific aspects of AS. Fatigue (40.0%), limited mobility (40.0%) and stiffness (30.0%) were also noted by patients as bothersome aspects of AS.
Many (40.0%) also reported experiencing moderate/severe impacts of AS on their ability to work. Attributes related to the process of treatment administration that were bothersome to patients include needing to refrigerate, needing to take daily, and maintaining insurance coverage/concerns about insurance not covering treatment, which were mentioned by one patient each. Patients reported trying a series of different treatments to find relief for their symptoms, and when they find something effective like injectables, they preferred to stay with that treatment type.Table 2Patient perceptions of AS and treatment administration processes: Selected verbatim quotes from qualitative interviews Bothersome disease- and treatment-related aspects of ASI would say the biggest thing is the unpredictability of it.
Of course, the pain and discomfort and the limitations that it imposes. (Patient 09)I've had to miss work because of it, just because of the pain and just not really being able to move or do anything or sleep throughout the night. (Patient 10)Bringing a refrigerated needle on a plane isn't the easiest thing all the time.
(Patient 02)Number two would probably be convenience, as far as medication goes. Just being able to constantly make sure that you're on insurance that will cover the medication. Having to explain every month that you’re on this medication, that, yes, you do still need it even though you’re feeling better.
(Patient 02)The frustrated part comes from knowing that you might have to try several before you find the right fit. There are so many different types of medications available, and not knowing what’s going to be effective for you. (Patient 03)[I feel] discouraged because I do know that it is a crapshoot where some things work.
(Patient 02)There are times when I’m optimistic, but there are times I’ve been really discouraged because you think, ‘Maybe this one is going to work.’ (Patient 07)Advantages and disadvantages of different processes of treatment administrationThe convenience factor. The once a month versus taking a pill every day is just more convenient to me. I’d kind of like a weekly injection because it’s a once-a-week, done with, over with sort of thing.
(Patient 09)If it was a medication that I didn’t have to keep refrigerated, that might make it a little easier for travel. (Patient 05)Having to get out to the doctor’s office. To go to the doctor’s office entails going through the worst traffic known to mankind.
Just to go down to that medical district is nerve-racking and time-consuming. The thought of going down there more often than I already do doesn’t sound appealing to me. It would be time-consuming, take me away from my job, and that sort of thing.
(Patient 09)I would still rather do the pill [than injection]; a pill is so much easier You’re just on a regimen. It’s just something you do every day… [taking a pill twice a day] would be no problem. I take plenty of other pills.
In the mornings, I probably take six and then at night, I probably take eight. (Patient 07)[I] probably would forget, but anything is better than injecting. A pill is easier to stash.
You take it with you, and you can just take it, even if you’re in a restaurant. You can’t do that with an injection. (Patient 01)AS ankylosing spondylitis
Advantages and Disadvantages of Attributes Related to the Process of Treatment Administration
Patients mentioned a variety of potential advantages and disadvantages of different modes of administration (Fig. 2). Administering injections at home was the most frequently mentioned advantage of self-injections (50.0%), with requiring refrigeration being the most cited disadvantage of this mode of administration (30.0%).
The only advantage attributed to infusions was the potential for less frequent administration, with 50.0% reporting that they would prefer infusion to be administered every 3–6 months; patients most often (80.0%) mentioned that the time and office visit required for each infusion were inconvenient. For an oral mode of administration, a variety of advantages were mentioned by patients, including being better for those with needle phobias, convenient for travel, and the ease of following the regimen (all mentioned by two patients each); the biggest disadvantage of an oral mode of administration was forgetting to take the medication, which was cited by 30.0% of patients. Patients perceived more advantages with self-injection and oral modes of administration than with infusion, for which disadvantages were primarily cited.Fig.
2Patients’ perceptions of the advantages and disadvantages of different modes of administration. Note. Patients could have mentioned > 1 advantage and/or disadvantage for each mode of administration.
Next to each bullet, the number and percentage of patients in the sample who mentioned each advantage and disadvantage are shown as ‘number (percentage value)’
Quantitative Patient Preference Survey
Study Sample
A total of 222 eligible patients completed the survey, and their data were reviewed for quality. It was determined that n = 12 records needed to be excluded from analyses due to the inability to distinguish their responses from random responding on the BWS choice tasks, which resulted in a final study sample of 210 eligible patients with AS. Patient characteristics are shown in Table 3.
Among 210 patients, half were male (50.0%), half were aged ≥ 42 years (50.0%), and the mean age of patients in the sample was 44.0 years. Most patients (93.3%) had poorly controlled disease (BASDAI score ≥ 4); 6.7% had well-controlled disease (BASDAI score < 4). Just over a third (37.6%) were currently on an advanced therapy.Table 3Patient characteristics: Quantitative surveyTotal sampleOn AT/well controlledOn AT/not well controlledNot on AT/not well controlled(N = 210)(N = 14)(N = 65)(N = 131)%n%n%n%nSexMale50.0%10557.1%847.7%3150.4%66Female50.0%10542.9%652.3%3449.6%65Age group* < 42 years50.0%10564.3%944.6%2951.1%67 ≥ 42 years50.0%10535.7%555.4%3648.9%64AgeMean (SD)44.3 (12.9)21040.1 (11.5)1446.1 (11.5)6543.9 (13.7)131Min, Max20, 7221027, 641424, 726520, 69131CountryUS71.4%15071.4%1067.7%4473.3%96Italy14.3%300.0%09.2%618.3%24UK14.3%3028.6%423.1%158.4%11BASDAI scoreMean (SD)5.9 (1.6)2102.4 (0.9)145.9 (1.2)656.3 (1.3)131Min, Max1, 102101, 4144, 9654, 10131“Well controlled” is defined as BASDAI score < 4; “not well controlled” is defined as BASDAI score ≥ 4.
AT advanced therapy, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, SD standard deviation, UK United Kingdom, US United States*Age 42 was used as the cut-off point based on the mean age of patients with AS in a prior phase 3 trial for tofacitinib [24]
Preferences for Attributes Related to the Process of Treatment Administration
Full Sample
BWS results showed that ‘treatment taken once a month’ was liked most (RI: 14.4) among the items included in the study, followed by ‘treatment taken orally (by mouth)’ (RI: 13.6) and ‘treatment does not need to be taken at a doctor’s office or clinic’ (RI: 13.1) (Fig. 3i). When comparing different modes and frequencies of administration of AS treatment in the fixed-choice tasks, patients preferred a once-a-day pill over self-injection but preferred both a twice-monthly or once-monthly self-injection to pill taken twice-a-day demonstrating that both mode and frequency of administration impact preferences (Table 4).Fig.
3Relative importance of AS treatment attributes for (i) the total sample and (ii) by treatment/disease status. Note. A score of 8.3 (100/12) reflects neutral, relative to the other attributes; scores > 8.3 reflect that a patient is more likely to like it (most liked), and scores < 8.3 reflect that a patient is more likely to dislike it (least liked).
The top 3 most important attributes for each group are denoted in ascending order of importance as ‘1’, ‘2’, and ‘3’. Relative importance estimates sum to 100 across attributes. Error bars represent 95% confidence intervals.
AS ankylosing spondylitis, AT advanced therapy. *p < 0.05; **p < 0.01Table 4Fixed-choice task responses: Total sample and by treatment/disease statusPreferencesTotal sampleAdvanced treatment/well-controlled diseaseAdvanced treatment/not well-controlled diseaseNo advanced treatment/not well-controlled diseaseN = 210n = 14n = 65n = 131% (n)% (n)% (n)% (n)Fixed-choice Task 1Option A: Pill once a day vs. Option B: Self-injection twice a monthStrongly prefer/prefer Option A55.7% (117)7.1% (1)40.0% (26)68.7% (90)No preference/neutral9.5% (20)14.3% (2)15.4% (10)6.1% (8)Strongly prefer/prefer Option B34.8% (73)78.6% (11)44.6% (29)25.2% (33)Fixed-choice Task 2Option A: Pill once a day vs. Option B: Pill twice a dayStrongly prefer/prefer Option A81.4% (171)92.9% (13)83.1% (54)79.4% (104)No preference/neutral12.9% (27)7.1% (1)13.8% (9)13.0% (17)Strongly prefer/prefer Option B5.7% (12)0.0% (0)3.1% (2)7.6% (10)Fixed-choice Task 3Option A: Pill once a day vs.
Option B: Self-injection once a monthStrongly prefer/prefer Option A48.1% (101)7.1% (1)30.8% (20)61.1% (80)No preference/neutral11.4% (24)7.1% (1)9.2% (6)13.0% (17)Strongly prefer/prefer Option B40.5% (85)85.7% (12)60.0% (39)26.0% (34)Fixed-choice Task 4Option A: Self-injection twice a month vs. Option B: Pill twice a dayStrongly prefer/prefer Option A40.0% (84)92.9% (13)49.2% (32)29.8% (39)No preference/neutral12.4% (26)0.0% (0)16.9% (11)11.5% (15)Strongly prefer/prefer Option B47.6% (100)7.1% (1)33.8% (22)58.8% (77)Fixed-choice Task 5Option A: Self-injection twice a month vs. Option B: Self-injection once a monthStrongly prefer/prefer Option A3.3% (7)7.1% (1)6.2% (4)1.5% (2)No preference/neutral8.6% (18)7.1% (1)10.8% (7)7.6% (10)Strongly prefer/prefer Option B88.1% (185)85.7% (12)83.1% (54)90.8% (119)Fixed-choice Task 6Option A: Pill twice a day vs.
Option B: Self-injection once a monthStrongly prefer/prefer Option A35.7% (75)0.0% (0)13.8% (9)50.4% (66)No preference/neutral14.8% (31)0.0% (0)16.9% (11)15.3% (20)Strongly prefer/prefer Option B49.5% (104)100.0% (14)69.2% (45)34.4% (45)Fixed-choice tasks were presented to patients in randomized order. “Well controlled” is defined as BASDAI score < 4; “not well controlled” is defined as BASDAI score ≥ 4. BASDAI Bath Ankylosing Spondylitis Disease Activity Index
Treatment/Disease Status
When comparing RI estimates for BWS attributes by treatment/disease status (i.e., advanced treatment/well-controlled disease vs. advanced treatment/not well-controlled disease vs. no advanced treatment/not well-controlled disease), there was some overlap in the treatment attributes that were most preferred by all groups (Fig. 3ii). Those in the no advanced treatment/not well-controlled disease group most preferred ‘treatment taken orally (by mouth)’ (RI: 16.5), followed by ‘treatment does not need to be taken at a doctor’s office or clinic’ (RI: 13.4) and ‘treatment taken once a month’ (RI: 13.1).
For those on advanced treatment/not well-controlled disease and those on advanced treatment/well-controlled disease, ‘treatment taken once a month’ (RI: 16.1 and 19.0), followed by ‘treatment does not need to be taken at a doctor’s office or clinic’ (RI: 11.7 and 17.5) and ‘treatment taken by self-injection (under the skin)’ (RI: 11.3 and 16.4) were the most preferred treatment attributes.
Statistically significant differences by treatment/disease status were observed for several attributes in the BWS choice tasks (Fig. 3ii). Patients in the no advanced treatment/not well-controlled disease group had a significantly stronger preference for ‘treatment taken orally (by mouth)’ than either of the groups who were on advanced therapy, and they preferred ‘treatment taken once a day’ and ‘treatment taken twice a day’ significantly more than patients on advanced therapy/well-controlled disease.
Those on advanced treatment/not well-controlled disease had a significantly stronger preference for ‘treatment taken once a month’, ‘treatment taken by self-injection (under the skin)’, and ‘treatment taken twice a month’ than patients not on advanced therapy/not well-controlled disease, and they had a stronger preference for ‘treatment taken once a day’ and ‘treatment taken twice a day’ than patients on advanced therapy/well-controlled disease. Patients on advanced therapy/well-controlled disease had a stronger preference for ‘treatment taken once a month’, ‘treatment taken by self-injection (under the skin)’, and ‘there is no chance of accidentally wasting a dose’ than patients in the no advanced treatment/not well-controlled disease group.
In the fixed-choice task responses, a greater percentage of patients with advanced treatment/well-controlled disease preferred ‘self-injection twice a month’ over ‘pill once a day’ than the other two groups (Table 4). When selecting between ‘pill once a day’ and ‘self-injection once a month’, those with no advanced treatment/not well-controlled disease preferred ‘pill once a day’ more than the other two groups. Even when the frequency of administration increased to ‘pill twice a day’, a majority of patients in the no advanced treatment/not well-controlled disease group still preferred the oral over either of the SC modes of administration.
When choosing between ‘pill twice a day’ and ‘self-injection once a month’, all respondents with advanced treatment/well-controlled disease preferred injection over pill.
Age Group
During a comparison of RI estimates for BWS attributes by age group, a statistically significant difference by age was observed in only one attribute, ‘treatment is easy to fit in your coat pocket’, which was more important to patients aged < 42 years than those aged ≥ 42 years (RI: 4.0 vs. 2.9, p = 0.026), but this attribute was less important than most other attributes for both age groups. Younger and older patients had similar preferences on the BWS and fixed-choice tasks.
Sex
Comparisons of RI estimates by sex showed a statistically significant difference on one attribute, ‘treatment does not need to be kept refrigerated’, which was more influential for female than for male patients (RI: 7.3 vs. 6.0, p = 0.041), although this attribute was less important than several other attributes for both groups (Supplementary Fig. 1).
The preferences of male and female patients were aligned regarding the attributes that were most influential, and the pattern of results on the fixed-choice tasks was similar for both groups (Supplementary Table 1).
Discussion
Although there is substantial evidence regarding patient preferences for treatment administration in other rheumatic diseases, there is a paucity of research on the treatment preferences of patients with AS. Many patients with AS have inadequately controlled disease despite the availability of effective treatments [8], with the introduction of effective treatment options varying in modes and frequencies of administration further highlighting the need to better understand patients’ treatment preferences. The current study, which incorporated multiple methodologies and included a multinational sample of patients who had a confirmed AS diagnosis, found that patients with AS endure a high disease burden with detrimental impacts, including pain, fatigue, and limited mobility.
Of importance, experiencing pain and fatigue is associated with poor quality of life and physical functioning among patients with AS [25]. Furthermore, patients feel as though they have little control over their condition, and this perception is driven by the pain and unpredictability of AS. Patients expressed that they must plan their lives around the disease, with daily routines shaped by the need for medication refrigeration and daily administration.
Patients with AS also commonly reported moderate to severe work impacts or not working at all due to their disease. Collectively, these findings were consistent with a recent analysis of pooled phase 2 and phase 3 tofacitinib clinical trial data in which greater AS pain and disease activity were associated with greater work productivity loss and impairment of non-work daily activities [3]. As such, to mitigate this burden, the optimal AS treatment for a given patient will need to reduce pain and provide better disease control.
The qualitative results further indicated that patients generally perceived less frequent administration and not requiring refrigeration as advantages. Patients who may prefer a pill over injection include those with active lifestyles who travel frequently or those who do not like needles. In addition, patients who have limited treatment experience may also be more likely to prefer oral over injection.
These findings thus support the need to align the choice of AS treatment with the needs, lifestyle, and preferences of the individual patient.
Results from the quantitative survey demonstrated that, when making treatment decisions, patients take different attributes into consideration. Patients regarded ‘treatment taken once a month’, ‘treatment taken orally (by mouth) once a day’, and ‘treatment does not need to be taken at a doctor’s office or clinic’ as the most important attributes when making AS treatment decisions. Overall, there was a preference for pill over self-injection, but when there was a stark difference in dosing frequency between the two modes of administration, patient preferences shifted towards a treatment with less frequent administration (e.g., self-injection once a month preferred over a pill twice a day).
This was consistent with findings from the qualitative interviews in which patients perceived less frequent administration as advantageous, as well as prior research showing that patients with endocrine or inflammatory diseases preferred oral over injectable mode of administration [26]. These results were likewise consistent with prior studies that examined treatment preferences in general inflammatory disease areas, including patients with AS, which have also determined that attributes related to the process of treatment administration and mode of administration are important to patients when making treatment decisions [9, 10, 12]. Findings were also in line with a prior patient preference study in which patients with r-axSpA more often preferred an oral pill than SC injection or infusion [11].
Study findings suggested that the importance of AS treatment attributes, as assessed via BWS choice tasks, are generally similar for older and younger patients despite increases in disease activity associated with age [1]. Furthermore, the preferences of male and female patients were mostly consistent. Prior research has shown sex differences in clinical characteristics and patient-reported outcomes [27], as well as differential impact on some aspects of physical function [28].
Hence, the similarity of preferences by sex observed in the current study is notable and suggests that preferences for attributes related to AS treatment administration generalize across sexes, although further research would need to confirm whether the findings generalize to patients who do not identify as cis-gender male or female.
Findings showed that preferences can differ considerably by treatment/disease status. Attributes, such as ‘treatment taken once a month’, ‘treatment does not need to be taken at doctor’s office or clinic’ were important across all three treatment/disease status groups. Nonetheless, differences in RI estimates for the other attributes varied by subgroup, indicating that the perceived value of AS treatment features may differ based on patients’ current AS treatment and the extent to which that treatment controls their disease.
There were several advantages of using a BWS exercise to elicit preferences. BWS can accommodate a larger number of attributes than alternative approaches, such as discrete choice experiments. BWS was an appropriate methodology for this study because we sought to elicit the perceived importance of each attribute relative to other attributes and not trade-offs between desirable and undesirable treatment features.
Attributes are converted to the same scale in BWS, which enables evaluation of their overall influence, rather than being evaluated apart from the utility gains/losses associated with other attributes [16, 17]. Moreover, BWS obtains preference/importance scores for multiple items, such as treatment features and/or outcomes; this yields a rank ordering of the importance of selected treatment attributes, which is used to estimate the RI of these attributes.
Treatment preferences, as assessed via fixed-choice tasks, also differed by treatment/disease status in a manner generally consistent with the BWS data, thereby lending further credibility to the observed pattern of results. Specifically, those on advanced treatment with well-controlled disease strongly preferred injectable over any oral options, suggesting these patients were satisfied with AS treatment delivered by self-injection. Patients on advanced treatment who do not have well-controlled disease preferred self-injections over oral, but to a much lesser degree than those with well-controlled disease.
In agreement with the qualitative interview findings, patients without advanced treatment experience preferred oral over injectable options.
Hence, findings from the subgroup analyses underscore the need to consider patient-specific factors, particularly disease control and current treatment, to inform AS treatment decision-making that aligns with patients’ preferences. Study results also provide potential directions for supporting shared decision-making for AS treatment and facilitating a more personalized approach to treatment selection for patients with AS. Given the evolving treatment landscape, future studies should identify independent predictors of preferences for the processes related to treatment administration to further understand which patients may be suitable candidates for currently available advanced therapies.
Overall, on average, patients with AS prefer oral options over self-injections, and they prefer less frequent administration. Approximately 50% of patients prefer a once-daily pill to a once-monthly injection. Patients on advanced therapy who have well-controlled disease appear to be satisfied with injectable treatments.
However, a sizeable proportion of patients who do not have well-controlled disease, whether on advanced therapy or not, prefer oral options over self-injections. Therefore, offering a daily oral pill option to patients whose disease is not well controlled may not only help to improve adherence among those currently taking an advanced therapy but may also overcome a potential barrier to initiating advanced therapy.
Limitations
The qualitative study findings are not intended to be generalizable; rather, they are meant to provide an in-depth depiction of patients’ perceptions of AS burden and treatment mode of administration. Nevertheless, efforts were made to recruit patients who represented the population of patients with AS in the US. It is possible that patients who participate in research more broadly are not representative, as they could be more educated or more vocal than those who choose not to participate in research.
Also, given the small sample sizes in qualitative research and the means of recruitment used in the present study, there may be aspects of the experience of people with AS that are not well represented in the qualitative study results. The qualitative phase of this research was conducted nearly 3 years ago, although we do not expect that the findings from the qualitative interviews would change if taken in the current time.
Selection bias may limit the ability to generalize results to the extent that the preferences of respondents who agreed to participate in the quantitative survey differ from individuals who chose not to participate. Furthermore, online patient-reported surveys may underrepresent individuals who lack internet access or who are uncomfortable using digital platforms, along with older adults in poorer health, those living in institutional settings, and individuals with severe comorbidities and disabilities. Due to reliance on convenience sampling methods, certain subgroups of patients with AS may be overrepresented or underrepresented, which may reduce the generalizability of the findings to the entire population of patients with AS.
Additionally, survey response rates could not be calculated; thus, the potential for non-response bias could not be ascertained. Self-reported data from respondents, including diagnosed comorbidities and treatment history, cannot be independently confirmed for accuracy.
While this study examined differences in preferences based on level of disease activity and treatment experience, observed differences in preferences could also be associated with other disease and socioeconomic characteristics. The BASDAI was used in the current study to assess disease activity. As such, we do not know whether the pattern of results would have differed had we used an alternative assessment to define disease activity, such as the AS Disease Activity Score (ASDAS), although the stark differences among treatment/disease status subgroups suggest that using a different assessment would not impact our conclusions.
Furthermore, ASDAS calculation requires C-reactive protein measurement, which is often not available at the time of seeing the patient. As a result, ASDAS is collected less often than BASDAI in routine rheumatology practice, suggesting our study may better reflect real-world disease activity assessment.
Fixed-choice tasks did not present an option for self-injection once a week (e.g., etanercept). Nevertheless, the aim of the fixed-choice tasks was to explore how patients would view more frequently administered oral options relative to less frequently administered self-injection options, rather than to compare all possible administration frequencies for available oral and self-injection AS treatment options. Subgroup comparisons by treatment/disease status should be interpreted with caution, given the small sample of patients on advanced treatment with well-controlled disease.
As most of the patients in this study did not have well-controlled disease, results may overrepresent the preferences of this patient subpopulation. While the BWS was designed to closely reflect clinical evidence regarding available AS treatments, it cannot capture all aspects involved in real-world AS treatment decisions. Lastly, while BWS can accommodate a larger number of attributes than other preference elicitation approaches, any unmeasured factors that influence AS treatment decisions may lead to error in the estimation of preferences.
Conclusions
The present mixed-methods study demonstrates that both AS and its treatment have wide-ranging impacts on patients. Notably, differences in patients’ treatment preferences depended on whether their disease was well controlled or not and whether they currently used advanced therapy or not. Most advanced therapy-naïve patients who do not have well-controlled disease had a strong preference for oral treatments, suggesting that injections may be a barrier to initiating advanced therapy.
For advanced therapy-experienced patients, avoiding injections is less of a priority than reducing injection frequency. Taken together, the findings from the current study enhance the understanding of patient preferences in treatment decision-making and support the need to better optimize AS treatment for each patient with respect to mode and frequency of administration.
Supplementary Information
Below is the link to the electronic supplementary material.Supplementary file1 (PDF 199 KB)